Teva Pharmaceutical (NYSE:TEVA) and Shanghai Fosun Pharmaceutical announced a collaboration on Monday to develop TEV-56278, a new therapy aimed at treating various cancers through an anti-PD1-IL2 attenukine approach.
According to the partnership agreement, Fosun Pharma will have exclusive rights to develop, manufacture, and